Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
OTC Drugs

FDA Surveys Cosmetic Products For Asbestos-Contaminated Talc

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

FDA is reviewing talc and talc-containing cosmetic products for asbestos contamination following reports of the carcinogen in cosmetics overseas

You may also be interested in...



Cosmetic Industry Panel's 2010 Priorities Include Triclosan, Talc

A cosmetic industry group's research panel set 17 priorities in the 300 ingredients it plans to evaluate in 2010 - including triclosan, used in antibacterial products and toothpastes and the subject of enduring controversy

Cosmetic Industry Panel's 2010 Priorities Include Triclosan, Talc

A cosmetic industry group's research panel set 17 priorities in the 300 ingredients it plans to evaluate in 2010 - including triclosan, used in antibacterial products and toothpastes and the subject of enduring controversy

Cosmetic Industry Panel's 2010 Priorities Include Triclosan, Talc

A cosmetic industry group's research panel set 17 priorities in the 300 ingredients it plans to evaluate in 2010 - including triclosan, used in antibacterial products and toothpastes and the subject of enduring controversy

Table

View full table

Related Content

HBW Insight
Pink Sheet

Topics

Tags:
OTC Drugs
Latest Headlines

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

National Drug Stockpiles Create ‘False Sense Of Security’

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

See All
UsernamePublicRestriction

Register

PS103916

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By